Assessing the Current and Future Trajectory of Imatinib Mesylate as a Cornerstone Therapy in Targeted Oncology: A Comprehensive Imatinib Drug Market Global Outlook The Imatinib Drug Market has undergone a transformative journey since the introduction of the first tyrosine kinase inhibitor (TKI), fundamentally altering the prognosis for patients diagnosed with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib, marketed originally as Gleevec, targets the BCR-ABL fusion protein in CML and c-KIT in GIST, offering a targeted approach with superior efficacy and reduced systemic toxicity compared to Ref - https://www.marketresearchfuture.com/reports/imatinib-drug-market-42762